Search Prime Grants

R01HL163814

Project Grant

Overview

Grant Description
SARS-CoV-2 Tropism in the Brain and Its Relationship to COVID-19 Pathogenesis

COVID-19 is a US and global disaster which has led to the deaths of almost a million individuals, including over 203,000 Americans, thus far. COVID-19 is caused by a novel beta-coronavirus (CoV) known as Severe Acute Respiratory Syndrome (SARS)-CoV-2, which was reported to cause severe pneumonia and lethal respiratory failure. Little is known about the disease mechanism of this virus and its disease mechanism.

In this application, we propose to test the effects of SARS-CoV-2 on the brain. We will develop multiple cell-type specific mouse models that express the SARS-CoV-2 receptor, human ACE2, in a cell-type specific manner. We will then use a variety of molecular, biochemical, histological, and neuroscience approaches to test the brain tropism of SARS-CoV-2 in depth and the effects of that on the central regulation of respiration.

This proposal will have a transformative impact on our current understanding of COVID-19 and its mechanisms of pathogenesis and will uncover important therapeutic targets.
Funding Goals
NOT APPLICABLE
Place of Performance
Massachusetts United States
Geographic Scope
State-Wide
Analysis Notes
COVID-19 $1,699,454 (39%) percent of this Project Grant was funded by COVID-19 emergency acts including the CARES Act.
Amendment Since initial award the End Date has been extended from 08/31/24 to 08/31/25 and the total obligations have increased 65% from $2,615,479 to $4,314,933.
Brigham & Womens Hospital was awarded SARS-CoV-2 Brain Tropism & COVID-19 Pathogenesis Project Grant R01HL163814 worth $4,314,933 from the National Institute of Allergy and Infectious Diseases in September 2021 with work to be completed primarily in Massachusetts United States. The grant has a duration of 4 years and was awarded through assistance program 93.310 Trans-NIH Research Support. The Project Grant was awarded through grant opportunity Change of Recipient Organization (Type 7 Parent Clinical Trial Optional).

Status
(Complete)

Last Modified 4/21/25

Period of Performance
9/25/21
Start Date
8/31/25
End Date
100% Complete

Funding Split
$4.3M
Federal Obligation
$0.0
Non-Federal Obligation
$4.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01HL163814

Subgrant Awards

Disclosed subgrants for R01HL163814

Transaction History

Modifications to R01HL163814

Additional Detail

Award ID FAIN
R01HL163814
SAI Number
R01HL163814-3186195005
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
QN6MS4VN7BD1
Awardee CAGE
0W3J1
Performance District
MA-90
Senators
Edward Markey
Elizabeth Warren

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Office of the Director, National Institutes of Health, Health and Human Services (075-0846) Health research and training Grants, subsidies, and contributions (41.0) $1,699,454 100%
Modified: 4/21/25